ROBINS HARLAN S 4

What Happened

Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies (ADPT), was issued a total of 837,033 shares as awards (no cash paid). The Form 4 reports two award acquisitions: 127,813 shares on 2026-03-04 and 709,220 shares on 2026-03-06, each recorded at $0.00 per share. These were grants/settlements (award code A), not open-market purchases or sales.

Key Details

• Transaction dates and amounts:
  • 2026-03-04: 127,813 shares acquired as an award at $0.00.
  • 2026-03-06: 709,220 shares acquired as an award at $0.00.
• Total shares acquired in this filing: 837,033.
• Shares owned after the transactions: not specified in the information provided in your prompt (check the full Form 4 for post-transaction holdings).
• Footnote: The performance share units (PSUs) were originally granted on March 6, 2023 for a three‑year performance period ending March 6, 2026. The issuer certified performance achievement and the PSUs vested on March 6, 2026 (each PSU converts to one share).
• Filing: Report filed 2026-03-06 (appears to be timely under Form 4 reporting rules).

Context

Performance share units are contingent compensation that convert to common stock when performance goals are met; these awards are common executive pay and are not cash purchases or sales. Because the shares were issued at $0, their economic value equals the market price of ADPT stock at vesting; that market value is not shown on the Form 4 and must be calculated separately if you want an estimated dollar amount. Awards like this reflect compensation and achievement of performance metrics, and should not be interpreted by themselves as a buy/sell signal.